Substituted pyridopyrrolopyrimidine ribonucleosides for therapeutic uses

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73607597" target="_blank" >RIV/61989592:15110/21:73607597 - isvavai.cz</a>
Result on the web
<a href="https://obd.upol.cz/id_publ/333187483" target="_blank" >https://obd.upol.cz/id_publ/333187483</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Substituted pyridopyrrolopyrimidine ribonucleosides for therapeutic uses
Original language description
Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl; and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers. Compounds according to the invention show strong cytostatic and cytotoxic effects on cell lines of tumor origin in a wide variety of diseases including tumors of different histogenetic origin.
Czech name
—
Czech description
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
2019235042
Publisher
AU001 -
Publisher name
IP Australia
Place of publication
Phillip ACT
Publication country
AU - AUSTRALIA
Date of acceptance
Jun 17, 2021
Owner name
Univerzita Palackého v Olomouci, Ústav organické chemie a biochemie AV ČR, v.v.i.
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)